Saudi Arabia Achieves Full Membership In ICMRA As First MENA Regulatory Authority

The Saudi Food and Drug Authority (SFDA) has achieved a significant milestone by becoming a full member of the International Coalition of Medicines Regulatory Authorities (ICMRA). This marks the first time a regulatory body from the Middle East and North Africa has attained such status. The SFDA's inclusion highlights Saudi Arabia's growing influence in global pharmaceutical regulation and drug safety.

During the ICMRA Annual Summit in Amsterdam, held from October 21 to 23, the announcement was made with Professor Hisham Aljadhey, CEO of SFDA, in attendance. Full membership allows the SFDA to actively participate in shaping ICMRA’s policies, approving projects, and contributing to global strategies that enhance regulatory efficiency and promote drug safety.

This achievement underscores Saudi Arabia's commitment to prioritising human health and safety. It also enhances the Kingdom’s involvement in international programs related to drug regulation and public health. The SFDA is dedicated to continuously improving its pharmaceutical regulatory system by adopting best practices globally.

The SFDA's accession supports the Health Sector Transformation Program, a key component of Saudi Vision 2030. By integrating further into the global pharmaceutical ecosystem, it strengthens its role in international decision-making and collaborative efforts to safeguard global health.

ICMRA is an international consortium comprising heads of medicines regulatory authorities worldwide. Its mission is to improve cooperation among member agencies to enhance the safety, effectiveness, and quality of medicines and vaccines. The coalition facilitates information exchange, supports innovation, expedites new treatments' approval, and unites efforts during public health emergencies.

The SFDA's membership reflects international recognition of Saudi Arabia’s progress in developing an advanced regulatory system aligned with global standards. This development reaffirms the authority’s dedication to anticipating future trends and ensuring high safety levels in drug manufacturing and distribution.

With this new role, Saudi Arabia can contribute significantly to international health policies. The Kingdom's leadership in pharmaceutical regulation is now acknowledged on a global scale, reinforcing its position as a key player in shaping international health initiatives.

With inputs from SPA